Blood Advances

Article	Citations
Complement C5 Inhibition in early onset HELLP Syndrome	173
Smith CC, Levis MJ, Perl AE, et al. Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib. Blood Adv. 2022;6(7):2144-2155.	169
Abramson JS, Siddiqi T, Garcia J, et al. Cytokine release syndrome and neurological event costs in lisocabtagene maraleucel–treated patients in the TRANSCEND NHL 001 trial. Blood Adv. 2021;5(6)	141
Transfusion therapy for sickle cell disease: what’s new?	132
Complete absence of GLUT1 does not impair human terminal erythroid differentiation	125
Selective modulation of activated protein C activities by a nonactive site–targeting nanobody library	123
Steroid tapering after GVHD Rx: not too fast, not too slow	114
Megakaryocyte/platelet-derived TGF-β1 inhibits megakaryopoiesis in bone marrow by regulating thrombopoietin production in liver	106
Genome editing of patient-derived iPSCs identifies a deep intronic variant causing aberrant splicing in hemophilia A	105
Relative dose intensity of obinutuzumab-chlorambucil in chronic lymphocytic leukemia: a multicenter Italian study	99
LMWH prevents thromboinflammation in the placenta via HBEGF-AKT signaling	98
Genome-wide whole-blood transcriptome profiling across inherited bone marrow failure subtypes	98
Addressing and overcoming disparities in GVHD	92
COVID-19 vaccination during therapy in relation to COVID-19 death in CLL	91
Conditioning intensity and probability of live birth after blood or marrow transplantation, a BMTSS report	89
Pediatric adapted risk index to predict 2-year transplant-related mortality post-HSCT in children	89
Cellular and humoral immune response to mRNA COVID-19 vaccination in subjects with chronic lymphocytic leukemia	88
Predictors of liver disease outcomes in individuals with hemophilia and HCV infection	87
On a collision course: SARS-CoV-2 variants and CAR T cells	86
Deletion of Y chromosome before allogeneic hematopoietic stem cell transplantation in male recipients with female donors	85
Long term outcome of Hyper-CVAD-R for Burkitt leukemia/lymphoma and high-grade B-cell lymphoma: focus on CNS relapse	83
International study of treatment efficacy in SS shows superiority of combination therapy and heterogeneity of treatment strategies	83
Deep PIM kinase substrate profiling reveals new rational cotherapeutic strategies for acute myeloid leukemia	79
Campbell BA, Dobos G, Haider Z, et al. International study of treatment efficacy in SS shows superiority of combination therapy and heterogeneity of treatment strategies. Blood Adv. 2023;7(21):	79
Pirillo C, Birch F, Tissot FS, et al. Metalloproteinase inhibition reduces AML growth, prevents stem cell loss, and improves chemotherapy effectiveness. Blood Adv. 2022;6(10):3126-3141.	79

Kennedy VE, Wong C, Huang C-Y, et al. Macrophage activation syndrome-like (MAS-L) manifestations following BCMA-directed CAR T cells in multiple myeloma. Blood Adv. 2021;5(23):5344-5348.	77
Glucagon-Like Peptide 1 Receptor Agonists and Venous Thromboembolism in Type 2 Diabetes: A Target Trial Emulation	76
Inaticabtagene autoleucel in adult relapsed or refractory B-cell acute lymphoblastic leukemia	75
Treatment strategies and outcome in relapsed peripheral T-cell lymphoma: results from the Netherlands Cancer Registry	75
Impact of Vein-to-vein Time in Patients With R/R LBCL Treated With Axicabtagene Ciloleucel	75
Reduced FVIII recovery associated with anti-FVIII PEG antibodies after BNT162b2 SARS-CoV-2 vaccination	74
Prognostic role of interim PET in patients with follicular lymphoma: a post-hoc study of FOLL12 trial by FIL	74
Desensitization to calaspargase pegol appears to be less successful than pegaspargase	73
Genetic landscapes and curative effect of CAR T-cell immunotherapy in patients with relapsed or refractory DLBCL	73
Targeting hypersialylation in multiple myeloma represents a novel approach to enhance NK cell–mediated tumor responses	72
Dasatinib/prednisone induction followed by blinatumomab/dasatinib in Ph+ acute lymphoblastic leukemia	71
The A-HIPI prediction model in advanced-stage Hodgkin lymphoma: identification of risk groups and creation of an online tool	71
Characteristics and outcomes of patients with CLL and CDKN2A/B deletion by fluorescence in situ hybridization	65
Sickle cell disease is a risk factor for transplant-associated thrombotic microangiopathy in children	65
Mitigating T-Cell Mitochondrial Dysfunction in CLL to Augment CAR T-Cell Therapy: Evaluation in an Immunocompetent Model	65
Best but not perfect: indirect measure of low iron stores	65
Chimeric antigen receptor T-cell therapy in adults with B-cell acute lymphoblastic leukemia	63
Second malignancies among older patients with classical myeloproliferative neoplasms treated with hydroxyurea	62
BCL11A promotes myeloid leukemogenesis by repressing PU.1 target genes	61
Plasma and rhADAMTS13 reduce trauma-induced organ failure by restoring the ADAMTS13-VWF axis	61
A novel 3D culture model recapitulates primary FL B-cell features and promotes their survival	59
The OHI index predicts early mortality from organ dysfunction and survival benefit from etoposide in lymphoma patients	59
Long term follow-up of MRD guided treatment of Ibrutinib plus Venetoclax for Relapsed CLL: phase 2 VISION/HO141 trial	59
Deferiprone for transfusional iron overload in sickle cell disease and other anemias: open-label study of up to 3 years	58
Molecular subclusters of follicular lymphoma: a report from the United Kingdom’s Haematological Malignancy Research Network	58
Applying CRISPR-Cas9 screens to dissect hematological malignancies	57
Low neutralizing activity of AZD7442 against current SARS-CoV-2 Omicron variants in patients with B-cell malignancies	57
Structural analysis of platelet fragments and extracellular vesicles produced by apheresis platelets during storage	56
ASCT vs CART for patients with relapsed LBCL in PR: role of TMTV	54
Mutations in myeloid transcription factors and activated signaling genes predict chronic myeloid leukemia outcomes	54
Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma	54
Higher doses of tisagenlecleucel are associated with improved outcomes: a report from the pediatric real-world CAR consortium	54
Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia	54
Bite-size introduction to canine hematologic malignancies	53
Converting IMPROVE bleeding and VTE risk assessment models into a fast-and-frugal decision tree for optimal hospital VTE prophylaxis	53
CD58 loss in tumor cells confers functional impairment of CAR T cells	53
Impact of Post-Transplant Cyclophosphamide-Based GVHD Prophylaxis in Patients 70 years and Older: An Update from BMT CTN 1703	53
Matrix stiffness controls megakaryocyte adhesion, fibronectin fibrillogenesis, and proplatelet formation through Itgβ3	53
Long-term survival with sickle cell disease: a nationwide cohort study of Medicare and Medicaid beneficiaries	53
Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML	53
Return emergency department visits for recurrent pulmonary embolism symptoms in children and adolescents	52
Donor age contributes more to the rheological properties of stored red blood cells than donor sex and biological age distribution	52
Longitudinal clinical data improve survival prediction after hematopoietic cell transplantation using machine learning	52
Uptake of long-chain fatty acids from the bone marrow suppresses CD8+ T-cell metabolism and function in multiple myeloma	52
Long-term real-world evidence of CPX-351 of high-risk patients with AML identified high rate of negative MRD and prolonged OS	52
An αIIbβ3 Ligand-Mimetic Murine Monoclonal Antibody That Produces Platelet Activation by Engaging the FcγIIa Receptor	52
Real-world results of CAR T-cell therapy for large B-cell lymphoma with CNS involvement: a GLA/DRST study	51
High frequency of central nervous system involvement in transformed Waldenström macroglobulinemia	51
Allogeneic hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a CIBMTR analysis	51
U2AF1 and EZH2 mutations are associated with nonimmune hemolytic anemia in myelodysplastic syndromes	50

Mitochondrial dsRNA from B-ALL cells stimulates mesenchymal stromal cells to become cancer-associated fibroblasts	50
Code status transitions in patients with high-risk acute myeloid leukemia	50
The ISHLT chronic lung allograft dysfunction consensus criteria are applicable to pulmonary chronic graft-versus-host disease	50
PD-1 Inhibition for Relapse after Allogeneic Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndrome	50
CAR T-cell therapy for secondary CNS DLBCL	50
Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma	49
Implementation of hospital-based sickle cell newborn screening and follow-up programs in Haiti	49
FBXW7β isoform drives transcriptional activation of the proinflammatory TNF cluster in human pro-B cells	49
Comparison of haploidentical and umbilical cord blood transplantation after myeloablative conditioning	49
Sustained hematologic remission after discontinuation of sutimlimab treatment in patients with cold agglutinin disease	49
Genomic landscape of patients with germline RUNX1 variants and familial platelet disorder with myeloid malignancy	49
Adaptation of Serious Illness Care Program to be delivered via telehealth for older patients with hematologic malignancy	49
Cumulative donor-specific antibody threshold predicts platelet transfusion response in HLA-alloimmunized patients	48
G3BP2-KIT drives leukemia amenable to kinase inhibition in Ph-like ALL	48
Commentary on the ASH ISTH NHF WFH 2021 guidelines on the diagnosis of VWD: reflections based on recent contemporary test data	48
Antileukemic properties of the kinase inhibitor OTSSP167 in T-cell acute lymphoblastic leukemia	48
Epigenetic features support the diagnosis of B-cell prolymphocytic leukemia and identify 2 clinicobiological subtypes	47
Establishment of a predictive model for GVHD-free, relapse-free survival after allogeneic HSCT using ensemble learning	47
Another step toward frontline BTK inhibitor therapy in MCL	47
Evaluating complement dysregulation in livedoid vasculopathy using a functional assay	47
Myb drives B-cell neoplasms and myeloid malignancies in vivo	47
Mutant PIK3CA is a targetable driver alteration in histiocytic neoplasms	46
Distinguishing STAT3/STAT5B-mutated large granular lymphocyte leukemia from myeloid neoplasms by genetic profiling	45
Association between hemoglobin values and VWF assays: a multicenter investigation	45
EMD originates from hyaluronan-induced homophilic interactions of CD44 variant-expressing MM cells under shear stress	45
Trends in volumes and survival after hematopoietic cell transplantation in racial/ethnic minorities	44
Dasatinib-induced spleen contraction leads to transient lymphocytosis	44
D-dimer for patients on VKA vs DOAC: impact on the validity of D-dimer to make decision for extended anticoagulation	44
Hasselbalch HC, Kristiansen MH, Kjær L, et al. CHIP-JAK2V617F, chronic inflammation, abnormal megakaryocyte morphology, organ failure, and multimorbidities. Blood Adv. 2024;8(3):681-682.	43
Cleavage of talin by calpain promotes platelet-mediated fibrin clot contraction	43
Horwitz SM, Scarisbrick JJ, Dummer R, et al. Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician’s choice in cutaneous T-cell lymphoma: final data. Blood Adv. 2021;5(23):5098-5	43
Graft-versus-host disease may cause pulmonary restriction, but not all restriction is graft-versus-host disease	43
Candidate germline biomarkers of lenalidomide efficacy in mantle cell lymphoma: the Fondazione Italiana Linfomi MCL0208 trial	43
Opposing effects of KDM6A and JDP2 on glucocorticoid sensitivity in T-ALL	42
Longitudinal analysis of cardiac abnormalities in pediatric patients with sickle cell anemia and effect of hydroxyurea therapy	42
Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia	42
High pulmonary hypertension risk by echocardiogram shortens survival in polycythemia vera	42
Impaired exercise capacity in post–COVID-19 syndrome: the role of VWF-ADAMTS13 axis	41
Fanconi anemia neuroinflammatory syndrome: brain lesions and neurologic injury in Fanconi anemia	41
AMPK drives both glycolytic and oxidative metabolism in murine and human T cells during graft-versus-host disease	41
Pharmacokinetics, pharmacodynamics, safety, and efficacy of crizanlizumab in patients with sickle cell disease	41
Cost-effectiveness of chimeric antigen receptor T-cell therapy in adults with relapsed or refractory follicular lymphoma	41
A phase 1 study of donor regulatory T-cell infusion plus low-dose interleukin-2 for steroid-refractory chronic graft-vs-host disease	41
Tumor-associated antigen–specific T cells with nivolumab are safe and persist in vivo in relapsed/refractory Hodgkin lymphoma	40
Transcriptomic analysis reveals proinflammatory signatures associated with acute myeloid leukemia progression	40
Myeloablative fractionated busulfan for allogeneic stem cell transplant in older patients or patients with comorbidities	40
Long live the red blood cell: biotin tagging in SCD	40
RNA-regulatory exosome complex suppresses an apoptotic program to confer erythroid progenitor cell survival in vivo	40
Extrinsic interactions in the microenvironment in vivo activate an antiapoptotic multidrug-resistant phenotype in CLL	40
HLA reduction of human T cells facilitates generation of immunologically multicompatible cellular products	40
Successful allogeneic hematopoietic stem cell transplantation in patients with VEXAS syndrome: a 2-center experience	40
Safety and efficacy of letetresgene autoleucel alone or with pembrolizumab for relapsed/refractory multiple myeloma	39
Salvage therapy with brentuximab-vedotin and bendamustine for patients with R/R PTCL: a retrospective study from the LYSA group	39
JMML tumor cells disrupt normal hematopoietic stem cells by imposing inflammatory stress through overproduction of IL-1β	39
A 69 long noncoding RNA signature predicts relapse and acts as independent prognostic factor in pediatric AML	39
Low frequency of Vγ9Vδ2 T cells predicts poor survival in newly diagnosed acute myeloid leukemia	38
DKK1 activates noncanonical NF-κB signaling via IL-6–induced CKAP4 receptor in multiple myeloma	38
Analysis of immune responses in patients with CLL after heterologous COVID-19 vaccination	38
Bilineal evolution of a U2AF1-mutated clone associated with acquisition of distinct secondary mutations	38
Alliance A061202: ixazomib, pomalidomide, and dexamethasone for patients with lenalidomide-refractory MM in first relapse	37
Effectiveness and safety of prophylactic anticoagulation among hospitalized patients with inflammatory bowel disease	37
Is estimated exposure an accurate surrogate for measured fludarabine levels in patients with CAR T-cell therapy?	37
The American Society of Hematology Health Equity Compendium: examining health equity across the Blood journals	37
Interactions between integrin α9β1 and VCAM-1 promote neutrophil hyperactivation and mediate poststroke DVT	37
Orthopedic toxicities among adolescents and young adults treated in DFCI ALL Consortium Trials	37
Bridging therapy before axi-cel for lymphoma	37
Factor XI inhibitors: a new class of anticoagulants	36
Commentary on the 2021 ASH Guidelines on use of anticoagulation in patients with COVID-19 being discharged from the hospital	36
HSCT using carrier donors for CD40L deficiency results in excellent immune function and higher CD40L expression in cTfh	36
Eculizumab for refractory thrombosis in antiphospholipid syndrome	36
Reduced-intensity conditioning hematopoietic stem cell transplantation for chronic lymphocytic leukemia and Richter’s transformation	36
Should we move to a genomic classification of neutrophilic myeloid neoplasms?	36
Patient-specific MDS-RS iPSCs define the mis-spliced transcript repertoire and chromatin landscape of SF3B1-mutant HSPCs	36
Digital pathology in pediatric nodular lymphocyte-predominant Hodgkin lymphoma: correlation with treatment response	36
World Coalition on SCD launches, sparking global focus on SCD diagnosis and care	36
Utility or futility? A contemporary approach to allogeneic hematopoietic cell transplantation for TP53-mutated MDS/AML	35
Prognostic impact of posttransplant FDG PET/CT scan in multiple myeloma	35
Incidence, clinical presentation, risk factors, outcomes, and biomarkers in de novo late acute GVHD	35
A CD3 humanized mouse model unmasked unique features of T-cell responses to bispecific antibody treatment	35
Evaluation of allogeneic and autologous membrane-bound IL-21–expanded NK cells for chronic lymphocytic leukemia therapy	35

Impact of race and social determinants of health on outcomes in patients with aggressive B-cell NHL treated with CAR-T therapy	35
Clinical outcomes of older and younger patients treated with loncastuximab tesirine in the LOTIS-2 clinical trial	35
Dual ASXL1 and CSF3R mutations drive myeloid-biased stem cell expansion and enhance neutrophil differentiation	35
PRMT5 inhibition drives therapeutic vulnerability to combination treatment with BCL-2 inhibition in mantle cell lymphoma	35
Role of radiotherapy to bulky sites of advanced Hodgkin lymphoma treated with ABVD: final results of FIL HD0801 trial	34
Early response markers predict survival after etoposide-based therapy of hemophagocytic lymphohistiocytosis	34
Risk of infectious adverse events of venetoclax therapy for hematologic malignancies: a systematic review and meta-analysis of RCTs	34
Characteristics, primary treatment, and survival of MDS/MPN with neutrophilia: a population-based study	34
Peritransplantation ruxolitinib administration is safe and effective in patients with myelofibrosis: a pilot open-label study	34
The use of FDA-approved medications for preventing vaso-occlusive events in sickle cell disease	34
Expanding donor options: haploidentical transplant recipients are also highly likely to have a 7/8-matched unrelated donor	34
Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy	34
Efficacy and safety of dapsone in adult primary immune thrombocytopenia	34
IgG testing, immunoglobulin replacement therapy, and infection outcomes in patients with CLL or NHL: real-world evidence	34
Daratumumab for immune thrombotic thrombocytopenic purpura	34
International consensus statement on the management of cardiovascular risk of Bruton’s tyrosine kinase inhibitors in CLL	34
Absolute lymphocyte count after BCMA CAR-T therapy is a predictor of response and outcomes in relapsed multiple myeloma	34
Combinatorial targeting of epigenome-modifying enzymes with decitabine and RN-1 synergistically increases HbF	34
Deciphering the regulatory landscape of murine splenic response to anemic stress at single-cell resolution	34
Immune profiling after allogeneic hematopoietic cell transplantation in pediatric acute myeloid leukemia	34
Genetically defined individual reference ranges for tryptase limit unnecessary procedures and unmask myeloid neoplasms	33
Effect of rabbit ATG PK on outcomes after TCR-αβ/CD19–depleted pediatric haploidentical HCT for hematologic malignancy	33
Lineage switching of the cellular distribution of BRAF V600E in multisystem Langerhans cell histiocytosis	33
Circulating tumor DNA predicts therapeutic outcome in mantle cell lymphoma	33
Vemurafenib combined with cladribine and cytarabine results in durable remission of pediatric BRAF V600E–positive LCH	33
Prognostic impact of patient-reported symptoms in multiple myeloma	32
Cytokine receptor IL27RA is an NF-κB–responsive gene involved in CD38 upregulation in multiple myeloma	32
Outpatient subcutaneous alemtuzumab is feasible and safe for aplastic anemia and is associated with high response rates	32
T-cell malignancies with anti-CD19 chimeric antigen receptor T-cell therapy	32
Cost-effectiveness of Voncento prophylaxis vs on-demand treatment in von Willebrand disease in the United Kingdom	32
Long-term outcomes of chemoimmunotherapy with obinutuzumab/chlorambucil in chronic lymphocytic leukemia	32
Gioacchino E, Koyunlar C, Zink J, et al. Essential role for Gata2 in modulating lineage output from hematopoietic stem cells in zebrafish. Blood Adv. 2021;5(13):2687-2700.	32
Tolerability and long-term disease control by IGHV mutation status among patients with CLL on ibrutinib arm of E1912	31
Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myeloma	31
TP53-mutant myelodysplastic syndrome and acute myeloid leukemia: the black hole of hematology	31
Mass spectrometry-detected MGUS is associated with obesity and other novel modifiable risk factors in a high-risk population	31
CD4+ CAR T-cell exhaustion associated with early relapse of multiple myeloma after BCMA CAR T-cell therapy	31
Tarlock K, Gerbing RB, Ries RE, et al. Prognostic impact of cooccurring mutations in FLT3-ITD pediatric acute myeloid leukemia. Blood Adv. 2024;8(9):2094-2103.	31
Implementing ASH's Guidelines for Acute Medical Care for Children and Adults with Sickle Cell Disease in Custody	31
Presentation of CXCL12γ by heparan sulfate proteoglycans activates CXCR4 without desensitization in B cells	31
Impact of detectable monoclonal protein at diagnosis on outcomes in marginal zone lymphoma: a multicenter cohort study	31
Thromboprophylaxis in hospitalized and nonhospitalized medical patients: what’s new?	31
Intermediate-Dose Post-Transplantation Cyclophosphamide for Myeloablative HLA-Haploidentical Bone Marrow Transplantation	31
Mature Megakaryocytes Acquire Immune Characteristics in a Mouse Model of Aplastic Anemia	31
Histiocytosis of the orbit and its association with KRAS mutations	31
Feasibility of high-dose methotrexate administered on day 1 of (R)CHOP in aggressive non-Hodgkin lymphomas	31
Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma	31
Cell-free DNA measurable residual disease as a predictor of postallogeneic hematopoietic cell transplant outcomes	31
Clinical features, pathophysiology, and therapy of poor graft function post–allogeneic stem cell transplantation	31
Real-world treatment patterns and outcomes in patients with primary hemophagocytic lymphohistiocytosis treated with emapalumab	31
Racial and socioeconomic status diversity and GVHD outcomes	31
Lissitchkov T, Willemze A, Katragadda S, et al. Efanesoctocog alfa for hemophilia A: results from a phase 1 repeat-dose study. Blood Adv. 2022;6(4):1089-1094.	31
Activity of luspatercept and ESAs combination for treatment of anemia in lower-risk myelodysplastic syndromes	30
Developing and validating a mortality prediction model for ICH in ITP: a nationwide representative multicenter study	30
Nivolumab plus relatlimab in patients with relapsed or progressed B-cell malignancies in RELATIVITY-022	30
Comparison of bone marrow and peripheral blood aberrant plasma cell assessment by NGF in patients with MM	30
Synonymous ADAMTS13 variants impact molecular characteristics and contribute to variability in active protein abundance	30
Molecular analysis of the erythroid phenotype of a patient with BCL11A haploinsufficiency	30
Associations between acute and chronic graft-versus-host disease	30
Improving eligibility criteria for first-line trials for patients with DLBCL using a US-based Delphi-method survey	30
Heightened TLR7 signaling primes BCR-activated B cells in chronic graft-versus-host disease for effector functions	30
Clinical care pathway for the evaluation of patients with suspected VITT after ChAdOx1 nCoV-19 vaccination	30
Histidine-rich glycoprotein: antithrombosis without bleeding	30
Outcomes in children with provoked venous thrombosis and antiphospholipid antibodies: findings from the Kids-DOTT trial	30
Anticoagulant therapy in patients with congenital FXI deficiency	29
Immunogenicity profile of rurioctocog alfa pegol in previously treated patients with severe congenital hemophilia A	29
Redundant mechanisms driven independently by RUNX1 and GATA2 for hematopoietic development	29
ICANS prophylaxis: potentially transformative but elusive	29
Transcriptomic atlas reveals organ-specific disease tolerance in sickle cell mice	29
Cotargeting EBV lytic as well as latent cycle antigens increases T-cell potency against lymphoma	29
Liver abnormalities are frequent and persistent in patients with Fanconi anemia	29
Do sophisticated models give the full picture of allogeneic hematopoietic stem cell transplantation effect?	29
Hereditary hemorrhagic telangiectasia may be the most morbid inherited bleeding disorder in women	29
Characterization and Treatment Outcomes of Malignant Histiocytoses in a Retrospective Series of 141 Cases in France	29
Evaluating real-world treatment patterns and outcomes of mantle cell lymphoma	29
Recombinant Erwinia asparaginase (JZP458) in ALL/LBL: complete follow-up of the Children’s Oncology Group AALL1931 study	29
Venetoclax enhances the efficacy of therapeutic antibodies in B-cell malignancies by augmenting tumor cell phagocytosis	29
Risk of posthospital venous thromboembolism in patients with COVID-19 varies by SARS-CoV-2 period and vaccination status	29
Autologous stem cell transplantation in T-cell/histiocyte-rich large B-cell lymphoma: EBMT Lymphoma Working Party study	29
Air pollutant impact on disease characteristics and outcomes in patients with acute myeloid leukemia	29
The 2022 review of the 2019 American Society of Hematology guidelines on immune thrombocytopenia	29
Retained functional normal and preleukemic HSCs at diagnosis are associated with good prognosis in DNMT3AmutNPM1mut AMLs	28
Venous thromboembolism prophylaxis in sickle cell disease: a multicenter cohort study of adolescent inpatients	28
Role of NKG2D ligands and receptor in haploidentical related donor hematopoietic cell transplantation	28
Whole genome sequences discriminate hereditary hemorrhagic telangiectasia phenotypes by non-HHT deleterious DNA variation	28
The clinical and laboratory diagnosis of vaccine-induced immune thrombotic thrombocytopenia	28
Immunoglobulin replacement vs prophylactic antibiotics for hypogammaglobulinemia secondary to hematological malignancy	28
An inducible Cd79b mutation confers ibrutinib sensitivity in mouse models of Myd88-driven diffuse large B-cell lymphoma	28
The long-term efficacy and safety of nilotinib in pediatric patients with CML: a 5-year update of the DIALOG study	28
Consensus statement for the perinatal management of patients with α thalassemia major	28
Molecular diagnosis of T-cell lymphoma: a correlative study of PCR-based T-cell clonality assessment and targeted NGS	28
CAR T-cell therapy in mantle cell lymphoma with secondary CNS involvement: a multicenter experience	28
Identification of germline monoallelic mutations in IKZF2 in patients with immune dysregulation	27
INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph+ acute lymphoblastic leukemia	27
CNS bridging radiotherapy achieves rapid cytoreduction before CAR T-cell therapy for aggressive B-cell lymphomas	27